C4 Therapeutics, Inc. (CCCC): Results of Operations and Financial Condition
C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Present
How this was made
The 30-second read
Why it matters
Traders can update probabilities around 2027 clinical data delivery (MOMENTUM ORR expected in 2H 2027; Phase 1b dose escalation update in 2H 2026) and funding runway (Roche $20M upfront in May 2026; $33.5M net ATM proceeds in Q2).
Market read
The filing is a combined catalyst package: quarterly financials plus concrete trial timing and incremental cash inflows that can re-rate near-to-medium term risk for CCCC.
What to watch
ATM raises can be dilutive over time, and the financials emphasize ongoing losses, so valuation may remain sensitive to burn rate and future enrollment/response durability.
Background
The 8-K (Item 2.02) reports C4 Therapeutics’ second quarter 2026 financial results and business highlights for its lead TPD program cemsidomide in multiple myeloma, plus a Roche DAC collaboration update.
Ticker impact
C4 Therapeutics filed an 8-K with Q2 2026 results and updates, including Phase 2 MOMENTUM enrollment completion in 1Q 2027 and Roche DAC collaboration progress.
Moderate positive bias for CCCC as traders price in 2027 readout timing and the $20M Roche upfront plus $33.5M ATM proceeds.
New primary disclosures include Q2 financials, specific trial timing (enrollment completion and expected ORR window), and fresh capital/collaboration details that can shift risk and valuation expectations.
Market effects
Reinforces investor focus on targeted protein degradation (TPD) and degrader-antibody conjugate (DAC) partnerships, potentially supporting sentiment toward similar clinical-stage oncology platforms.
Limited direct regional impact; primarily affects US small/mid-cap biotech sentiment.
Roche collaboration highlights continued global pharma interest in next-generation modality partnerships, but the disclosure is company-specific.
Counterpoint
Despite positive trial and funding updates, the article does not provide new efficacy readouts for MOMENTUM; near-term catalysts are still largely 2027.
Key entities
- companyC4 Therapeutics, Inc.
Nasdaq-listed clinical-stage biopharmaceutical company reporting Q2 2026 results and cemsidomide trial/collaboration updates.
- assetcemsidomide
IKZF1/3 degrader in Phase 2 MOMENTUM and Phase 1b combination trials for relapsed refractory multiple myeloma.
- partnerRoche
Entered a collaboration agreement with C4 in April 2026; C4 received a $20M upfront payment in May 2026.
- therapyelranatamab (ELREXFIO)
CD3 targeted bispecific antibody used in a Phase 1b combination trial with cemsidomide.
